<table class="drug-table data-table table table-condensed table-bordered"><tbody><tr id="identification"><th class="divider" colspan="2">Identification</th></tr><tr><th>Name</th><td><strong>Methazolamide</strong></td></tr><tr><th>Accession Number</th><td><strong>DB00703</strong>&#160; (APRD00740)</td></tr><tr><th>Type</th><td>small molecule</td></tr><tr><th>Groups</th><td>approved</td></tr><tr><th>Description</th><td><p>A carbonic anhydrase inhibitor that is used as a diuretic and in the treatment of glaucoma. [PubChem]</p></td></tr><tr><th>Structure</th><td><div class="structure"><a class="moldbi-thumbnail" href="http://structures.wishartlab.com/molecules/DB00703/image.png"><img alt="Thumb" src="http://structures.wishartlab.com/molecules/DB00703/thumb.png"></a></div><div class="structure-links"><div class="btn-group btn-group-xs"><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00703.mol">MOL</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00703.sdf">SDF</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00703.pdb">PDB</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00703.smiles">SMILES</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00703.inchi">InChI</a><a class="btn btn-info" href="/structures/structures/small_molecule_drugs/DB00703">View Structure</a></div></div></td></tr><tr><th>Synonyms</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="synonyms"><thead><th>Synonym</th><th>Language</th><th>Code</th></thead><tbody><tr><td>Metazolamida</td><td>Spanish</td><td>INN</td></tr><tr><td>Methazolamid</td><td>German</td><td>INN</td></tr><tr><td>M&#233;thazolamide</td><td>French</td><td>INN</td></tr><tr><td>Methazolamidum</td><td>Latin</td><td>INN</td></tr></tbody></table></td></tr><tr><th>Salts</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Brand names</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="brands"><thead><tr><th>Name</th><th>Company</th></tr></thead><tbody><tr><td>Methazolamide</td><td>Teva</td></tr><tr><td>Naptazane</td><td>Fera Pharmaceuticals</td></tr><tr><td>Neptazane</td><td>Fera</td></tr></tbody></table></td></tr><tr><th>Brand mixtures</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Categories</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>CAS number</th><td>554-57-4</td></tr><tr><th>Weight</th><td>Average: 236.272<br>Monoisotopic: 236.003781522</td></tr><tr><th>Chemical Formula</th><td>C<sub>5</sub>H<sub>8</sub>N<sub>4</sub>O<sub>3</sub>S<sub>2</sub></td></tr><tr><th>InChI Key</th><td>FLOSMHQXBMRNHR-DAXSKMNVSA-N</td></tr><tr><th>InChI</th><td><div class="wrap">InChI=1S/C5H8N4O3S2/c1-3(10)7-4-9(2)8-5(13-4)14(6,11)12/h1-2H3,(H2,6,11,12)/b7-4-</div></td></tr><tr><th>IUPAC Name</th><td><div class="wrap">N-[(2Z)-3-methyl-5-sulfamoyl-2,3-dihydro-1,3,4-thiadiazol-2-ylidene]acetamide</div></td></tr><tr><th>SMILES</th><td><div class="wrap">CN1N=C(S\C1=N/C(C)=O)S(N)(=O)=O</div></td></tr><tr><th>Mass Spec</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="taxonomy"><th class="divider" colspan="2">Taxonomy</th></tr><tr><th>Kingdom</th><td>Organic Compounds</td></tr><tr><th>Superclass</th><td>Heterocyclic Compounds</td></tr><tr><th>Class</th><td>Azoles</td></tr><tr><th>Subclass</th><td>Thiadiazoles</td></tr><tr><th>Direct parent</th><td>Thiadiazoles</td></tr><tr><th>Alternative parents</th><td>Sulfonyls; Sulfonamides; Polyamines; Enolates; Carboxylic Acid Amides</td></tr><tr><th>Substituents</th><td>carboxamide group; enolate; polyamine; carboxylic acid derivative; amine; organonitrogen compound</td></tr><tr><th>Classification description</th><td>This compound belongs to the thiadiazoles. These are cyclic organic compounds containing a thiadiazole ring, which is a five-member aromatic heterocycle made up of one sulfur atom and two nitrogen atoms.</td></tr><tr id="pharmacology"><th class="divider" colspan="2">Pharmacology</th></tr><tr><th>Indication</th><td>For treatment of chronic open-angle glaucoma and acute angle-closure glaucoma</td></tr><tr><th>Pharmacodynamics</th><td>Methazolamide is topical carbonic anhydrase inhibitor. Methazolamide is indicated for the reduction of elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension who are insufficiently responsive to beta-blockers. Methazolamide is a sulfonamide derivative; however, it does not have any clinically significant antimicrobial properties. Although methazolamide achieves a high concentration in the cerebrospinal fluid, it is not-considered an effective anticonvulsant. Methazolamide has a weak and transient diuretic effect, therefore use results in an increase in urinary volume, with excretion of sodium, potassium and chloride.</td></tr><tr><th>Mechanism of action</th><td>Methazolamide is a potent inhibitor of carbonic anhydrase. Inhibition of carbonic anhydrase in the ciliary processes of the eye decreases aqueous humor secretion, presumably by slowing the formation of bicarbonate ions with subsequent reduction in sodium and fluid transport.</td></tr><tr><th>Absorption</th><td>Methazolamide is well absorbed from the gastrointestinal tract.</td></tr><tr><th>Volume of distribution</th><td><ul>
	<li>17 to 23 L</li>
</ul></td></tr><tr><th>Protein binding</th><td>55%</td></tr><tr><th>Metabolism</th><td class="data-table-container"></td></tr><tr><th>Route of elimination</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Half life</th><td>14 hours</td></tr><tr><th>Clearance</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Toxicity</th><td>Electrolyte imbalance, development of an acidotic state, and central nervous system effects might be expected to occur in the case of an overdose.</td></tr><tr><th>Affected organisms</th><td><ul><li>Humans and other mammals</li></ul></td></tr><tr><th>Pathways</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>SNP Mediated Effects</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>SNP Mediated Adverse Drug Reactions</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="admet"><th class="divider" colspan="2">ADMET</th></tr><tr><th>Predicted ADMET features</th><td class="data-table-container"><table class="table table-condensed table-striped" id="predicted-admet">
  <thead>
    <tr>
      <th>Property</th>
      <th>Value</th>
      <th>Probability</th>
    </tr>
  </thead>
  <tbody>
      <tr>
        <td>Human Intestinal Absorption</td>
        <td>
              +
        </td>
        <td>0.7104</td>
      </tr>
      <tr>
        <td>Blood Brain Barrier</td>
        <td>
              +
        </td>
        <td>0.8117</td>
      </tr>
      <tr>
        <td>Caco-2 permeable</td>
        <td>
              -
        </td>
        <td>0.6196</td>
      </tr>
      <tr>
        <td>P-glycoprotein substrate</td>
        <td>
            Non-substrate
        </td>
        <td>0.8509</td>
      </tr>
      <tr>
        <td>P-glycoprotein inhibitor I</td>
        <td>
            Non-inhibitor
        </td>
        <td>0.9245</td>
      </tr>
      <tr>
        <td>P-glycoprotein inhibitor II</td>
        <td>
            Non-inhibitor
        </td>
        <td>0.8896</td>
      </tr>
      <tr>
        <td>Renal organic cation transporter</td>
        <td>
            Non-inhibitor
        </td>
        <td>0.8909</td>
      </tr>
      <tr>
        <td>CYP450 2C9 substrate</td>
        <td>Non-substrate</td>
        <td>0.6189</td>
      </tr>
      <tr>
        <td>CYP450 2D6 substrate</td>
        <td>Non-substrate</td>
        <td>0.8512</td>
      </tr>
      <tr>
        <td>CYP450 3A4 substrate</td>
        <td>Non-substrate</td>
        <td>0.6898</td>
      </tr>
      <tr>
        <td>CYP450 1A2 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.9045</td>
      </tr>
      <tr>
        <td>CYP450 2C9 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.6861</td>
      </tr>
      <tr>
        <td>CYP450 2D6 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.9231</td>
      </tr>
      <tr>
        <td>CYP450 2C19 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.9025</td>
      </tr>
      <tr>
        <td>CYP450 3A4 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.8308</td>
      </tr>
      <tr>
        <td>CYP450 inhibitory promiscuity</td>
        <td>Low CYP Inhibitory Promiscuity</td>
        <td>0.8681</td>
      </tr>
      <tr>
        <td>Ames test</td>
        <td>
          Non AMES toxic 
        </td>
        <td>
            0.7032
        </td>
      </tr>
      <tr>
        <td>Carcinogenicity</td>
        <td>
          Non-carcinogens 
        </td>
        <td>
            0.7679
        </td>
      </tr>
      <tr>
        <td>Biodegradation</td>
        <td>
          Not ready biodegradable 
        </td>
        <td>
            0.9138
        </td>
      </tr>
      <tr>
        <td>Rat acute toxicity</td>
        <td>
          2.2388 
            LD50, mol/kg
        </td>
        <td>
            <span class="wishart wishart-not-available">Not applicable</span>
        </td>
      </tr>
      <tr>
        <td>hERG inhibition (predictor I)</td>
        <td>
          Weak inhibitor 
        </td>
        <td>
            0.9942
        </td>
      </tr>
      <tr>
        <td>hERG inhibition (predictor II)</td>
        <td>
          Non-inhibitor 
        </td>
        <td>
            0.9021
        </td>
      </tr>
  </tbody>
</table>
</td></tr><tr id="pharmacoeconomics"><th class="divider" colspan="2">Pharmacoeconomics</th></tr><tr><th>Manufacturers</th><td><ul><li>Applied analytical industries</li>
<li>Mikart inc</li>
<li>Sandoz inc</li>
<li>Teva pharmaceuticals usa</li>
<li>Lederle laboratories div american cyanamid co</li></ul></td></tr><tr><th>Packagers</th><td><ul><li><a href="http://www.akorn.com">Akorn Inc.</a></li>
<li>Effcon Laboratories Inc.</li>
<li><a href="http://www.ferapharma.com">Fera Pharmaceuticals</a></li>
<li>Heartland Repack Services LLC</li>
<li><a href="http://www.mikart.com">Mikart Inc.</a></li>
<li><a href="http://www.unitdosesupply.com">Murfreesboro Pharmaceutical Nursing Supply</a></li>
<li><a href="http://www.physicianstotalcare.com">Physicians Total Care Inc.</a></li>
<li><a href="http://www.prescript.net">Prescript Pharmaceuticals</a></li>
<li>Professional Co.</li>
<li><a href="http://www.worldoftest.com">Qualitest</a></li>
<li><a href="http://www.sandoz.ca">Sandoz</a></li>
<li><a href="http://www.tevapharm.com">Teva Pharmaceutical Industries Ltd.</a></li></ul></td></tr><tr><th>Dosage forms</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="dosages"><thead><tr><th>Form</th><th>Route</th><th>Strength</th></tr></thead><tbody><tr><td>Tablet</td><td>Oral</td><td></td></tr></tbody></table></td></tr><tr id="spectra"><th class="divider" colspan="2">Spectra</th></tr><tr><th>Spectra</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="interactions"><th class="divider" colspan="2">Interactions</th></tr><tr><th>Drug Interactions</th><td class="data-table-container"><table class="table table-condensed table-striped" id="experimental-properties"><thead><tr><th>Drug</th><th style="width: 75%"></th></tr></thead><tbody><tr><td><a href="/drugs/DB00945">Acetylsalicylic acid</a></td><td>Acetylsalicylic acid at high dose increases the effect of the carbonic anhydrase inhibitor, methazolamide.</td></tr><tr><td><a href="/drugs/DB01294">Bismuth Subsalicylate</a></td><td>The salicylate, bismuth subsalicylate, at high dose increases the effect of the carbonic anhydrase inhibitor, methazolamide.</td></tr><tr><td><a href="/drugs/DB01194">Brinzolamide</a></td><td>As both brinzolamide and methazolamide are carbonic anhydrase inhibitors, there is an increased risk of adverse effects.The development of acid-base disorders with concurrent use of ophthalmic and oral carbonic anhydrase inhibitors has been reported. Avoid concurrent use of different carbonic anhydrase inhibitors when possible.</td></tr><tr><td><a href="/drugs/DB01397">Magnesium salicylate</a></td><td>The salicylate, magnesium salicylate, at high dose increases the effect of the carbonic anhydrase inhibitor, methazolamide.</td></tr><tr><td><a href="/drugs/DB01043">Memantine</a></td><td>Possible increased levels of memantine</td></tr><tr><td><a href="/drugs/DB01398">Salicylate-sodium</a></td><td>The salicylate, salicylate-sodium, at high dose increases the effect of the carbonic anhydrase inhibitor, methazolamide.</td></tr><tr><td><a href="/drugs/DB01399">Salsalate</a></td><td>The salicylate, salsalate, at high dose increases the effect of the carbonic anhydrase inhibitor, methazolamide.</td></tr><tr><td><a href="/drugs/DB00374">Treprostinil</a></td><td>Additive hypotensive effect. Monitor antihypertensive therapy during concomitant use. </td></tr><tr><td><a href="/drugs/DB01401">Trisalicylate-choline</a></td><td>The salicylate, trisalicylate-choline, at high dose increases the effect of the carbonic anhydrase inhibitor, methazolamide.</td></tr></tbody></table></td></tr><tr><th>Food Interactions</th><td><ul><li>Take with food, more than 6 hours before bedtime increase liquid intake.</li></ul></td></tr></tbody></table>